Literature DB >> 27764046

68Ga-DOTATOC and 68Ga-PSMA PET/CT Unmasked a Case of Prostate Cancer With Neuroendocrine Differentiation.

Sirong Chen1, Shing Kee Cheung, Ka-Nin Wong, Kwok Kee Wong, Chi-Lai Ho.   

Abstract

A bedridden 90-year-old man with fever and elevated prostate-specific antigen (PSA) (49 ng/mL) was referred for differentiation between infection and tumor. F-FDG PET/CT was negative for infection, but Ga-PSMA PET/CT showed multiple lesions in prostate gland with infiltration to bladder wall and seminal vesicle, consistent with locally advanced prostate cancer. The lesion with the highest Ga-PSMA uptake was strongly avid for Ga-DOTATOC, suggesting neuroendocrine tumor differentiation. After hormonal therapy, PSA normalized, but chromogranin-A increased (from 251 to 398 ng/mL), inferring progression of neuroendocrine tumor differentiation. Advanced prostate cancer may require investigation for pathological neuroendocrine transformation, although PSA may suggest improvement.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27764046     DOI: 10.1097/RLU.0000000000001419

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  7 in total

1.  Obstructive Jaundice: An Unusual Presentation of Neuroendocrine Differentiation in Prostatic Adenocarcinoma.

Authors:  Sampath Santhosh; Godwin Jeeva; Ranjan Kumar Mohapatra
Journal:  Indian J Nucl Med       Date:  2021-03-04

Review 2.  Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging.

Authors:  Sara Sheikhbahaei; Ali Afshar-Oromieh; Matthias Eiber; Lilja B Solnes; Mehrbod S Javadi; Ashley E Ross; Kenneth J Pienta; Mohamad E Allaf; Uwe Haberkorn; Martin G Pomper; Michael A Gorin; Steven P Rowe
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-08-01       Impact factor: 9.236

3.  Comparison of 68Ga-PSMA-617 PET/CT with mpMRI for the detection of PCa in patients with a PSA level of 4-20 ng/ml before the initial biopsy.

Authors:  Yu Li; Donghui Han; Peng Wu; Jing Ren; Shuaijun Ma; Jingliang Zhang; Wei Song; Xiaoyu Lin; Dian Jiao; Shengjia Shi; Fa Yang; Jieheng Wu; Ping Meng; Weihong Wen; Fei Kang; Jing Wang; Weijun Qin
Journal:  Sci Rep       Date:  2020-07-03       Impact factor: 4.379

Review 4.  Multimodal imaging for radiation therapy planning in patients with primary prostate cancer.

Authors:  Constantinos Zamboglou; Matthias Eiber; Thomas R Fassbender; Matthias Eder; Simon Kirste; Michael Bock; Oliver Schilling; Kathrin Reichel; Uulke A van der Heide; Anca L Grosu
Journal:  Phys Imaging Radiat Oncol       Date:  2018-11-05

Review 5.  A Treatment Paradigm Shift: Targeted Radionuclide Therapies for Metastatic Castrate Resistant Prostate Cancer.

Authors:  Ephraim E Parent; Adam M Kase
Journal:  Cancers (Basel)       Date:  2022-09-01       Impact factor: 6.575

6.  Case Report: 18F-PSMA PET/CT Scan in Castration Resistant Prostate Cancer With Aggressive Neuroendocrine Differentiation.

Authors:  Marco Bergamini; Alberto Dalla Volta; Irene Caramella; Luisa Bercich; Simona Fisogni; Mattia Bertoli; Francesca Valcamonico; Salvatore Grisanti; Pietro Luigi Poliani; Francesco Bertagna; Alfredo Berruti
Journal:  Front Oncol       Date:  2022-07-22       Impact factor: 5.738

7.  Neuroendocrine Differentiation of Prostate Cancer Is Not Systematically Associated with Increased 18F-FDG Uptake.

Authors:  Matteo Bauckneht; Silvia Morbelli; Alberto Miceli; Sara Elena Rebuzzi; Giuseppe Fornarini
Journal:  Diagnostics (Basel)       Date:  2021-03-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.